基于β细胞为靶标的2型糖尿病药物治疗研究进展

Advancement on the therapy of type 2 diabetes by targeting β-cell mass

2型糖尿病是以进行性β细胞功能损害和β细胞数量和质量减少为特征的。当β细胞数量和质量减少到一定程度,剩余的β细胞不能维持正常血糖需要的数量时,增加β细胞数量和质量而不需要使用额外的降糖药将是唯一的选择。因此治疗糖尿病的最终目的是保护、修复、再生或替代β细胞的数量和功能,从而最有效地缓解或修复此疾病发展进程。本文将以β细胞为靶标对2型糖尿病药物治疗研究进展进行综述。

Type 2 diabetes is characterized by progressive β-cell dysfunction and a reduction in β-cell mass. If the β-cell mass is already below the threshold for maintaining normoglycemia,the expansion of β-cell mass is the only option for achieving normoglycemia without the use of additional glucose lowering agents. Therefore,the ultimate goal of therapies on type 2 diabetes is preserving,regenerating or replacing the β-cell mass. In this review,we address the mechanisms involved in β-cell dysfunction and β-cell loss,and provide a rationale for pharmacological intervention for the preservation and/or expansion of β-cell mass in type 2 diabetes.